Statements in which the resource exists as a subject.
PredicateObject
rdf:type
rdfs:label
Herceptin (Kit)
dailymed-instance:activeIng...
dailymed-instance:genericDr...
dailymed-instance:boxedWarn...
WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, AND PULMONARY TOXICITY: Cardiomyopathy Herceptin can result in sub���clinical and clinical cardiac failure manifesting as CHF and decreased LVEF. The incidence and severity of left ventricular cardiac dysfunction was highest in patients who received Herceptin concurrently with anthracycline containing chemotherapy regimens. Evaluate left ventricular function in all patients prior to and during treatment with Herceptin. Discontinue Herceptin treatment in patients receiving adjuvant therapy and strongly consider discontinuation of Herceptin treatment in patients with metastatic breast cancer for clinically significant decrease in left ventricular function. [see Warnings and Precautions ( 5.1) and Dosage and Administration ( 2.2)] Infusion Reactions; Pulmonary Toxicity Herceptin administration can result in serious infusion reactions and pulmonary toxicity. Fatal infusion reactions have been reported. In most cases, symptoms occurred during or within 24 hours of administration of Herceptin. Herceptin infusion should be interrupted for patients experiencing dyspnea or clinically significant hypotension. Patients should be monitored until signs and symptoms completely resolve. Discontinue Herceptin for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. [see Warnings and Precautions ( 5.2, 5.4)]
dailymed-instance:activeMoi...
dailymed-instance:inactiveI...
dailymed-instance:possibleD...
dailymed-instance:genericMe...
Trastuzumab
dailymed-instance:fullName
Herceptin (Kit)
dailymed-instance:represent...
dailymed-instance:routeOfAd...
dailymed-instance:name
Herceptin